I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.

Histogenics (HSGX) P3 Clinical Trial of Neocart® enrollment completed to Treat Knee Cartilage Damage - BUY

June 27, 2017

On track for top-line 1 year powered data and potential BLA filing in Q3/18 BLA to the FDA shortly thereafter and, if approved, launching NeoCart in the second half of 2019  

bluebird bio (BLUE) prices $350 M share offering at $105.00

June 26, 2017

BLUE closed down -$4.20 to $1.06.90 after Monday's -$0.90 or -0.80% to $111.10  

Sangamo Therapeutics (SGMO) proposes $72.5 M offering

June 20, 2017

SGMO closes UP +$0.25 to $8.20 and promptly dives -$0.70 or -8.54% to $7.50 ​SGMO prices 10 M shares at $7.25  

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.